Appraising the European randomized study of screening for prostate cancer: what do the results mean?
The value of screening for prostate cancer has been a contentious issue within the medical literature for several decades. At the crux of the matter lies a judgment call of whether the potential benefits of screening, a reduction in prostate cancer and all-cause mortality, outweigh the limitations,...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2015-04-01
|
| Series: | Asian Journal of Andrology |
| Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2015;volume=17;issue=2;spage=221;epage=222;aulast=Ilic |
| Summary: | The value of screening for prostate cancer has been a contentious issue within the medical literature for several decades. At the crux of the matter lies a judgment call of whether the potential benefits of screening, a reduction in prostate cancer and all-cause mortality, outweigh the limitations, overdiagnosis and overtreatment. The study by Schrφder et al. reports 9, 11 and 13-year follow-up data on men participating in the European randomized study of screening for prostate cancer (ERSPC). While the authors report a significant reduction in prostate cancer mortality, they conclude that potential harms associated with screening currently circumvent any recommendation for a population-based approach to screening for prostate cancer. |
|---|---|
| ISSN: | 1008-682X 1745-7262 |